You just read:

NOVAVAX Awarded HHS-BARDA Contract Valued at up to $179 Million to Develop Pandemic and Seasonal Influenza Vaccines for U.S. Government Using Recombinant VLP Technology

News provided by

Novavax, Inc.

Mar 01, 2011, 08:30 EST